Literature DB >> 2516852

Growth inhibition and differentiation of murine melanoma B16-BL6 cells caused by the combination of cisplatin and caffeine.

H Tsuchiya1, K Tomita, H Yasutake, Y Ueda, M Tanaka, T Sasaki.   

Abstract

We preliminarily investigated the combined effects of cisplatin and caffeine on murine melanoma B16-BL6 cells in vitro. When caffeine was added before or simultaneously with cisplatin, there was little growth inhibition. The addition of 2.0 mM caffeine after 1 h of exposure to cisplatin inhibited growth and induced cell differentiation. This treatment resulted in fewer cells, and the numbers of melanosomes and mitochondria and the amount of Golgi's complex and endoplasmic reticulum were increased. DNA histograms obtained by flow cytometry showed that cells treated with cisplatin alone accumulated in the G2/M phase, with a partial G2 block. The addition of 2.0 mM caffeine after 1 h of treatment with cisplatin reduced this block. Caffeine caused murine melanoma B16-BL6 cells treated with cisplatin to differentiate, and this inhibited growth.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2516852      PMCID: PMC5917928          DOI: 10.1111/j.1349-7006.1989.tb01661.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  11 in total

1.  Chemical inducers of differentiation, dimethylsulfoxide, butyric acid, and dimethylthiourea, induce selective ultrastructural patterns in B16 melanoma cells.

Authors:  H Malik; J Nordenberg; A Novogrodsky; A Fuchs; Z Malik
Journal:  Biol Cell       Date:  1987       Impact factor: 4.458

2.  [The combined effect of anti-tumor agents with caffeine or calcium channel blockers on sarcoma cells by clonogenic assay].

Authors:  H Tsuchiya; K Tomita
Journal:  Nihon Gan Chiryo Gakkai Shi       Date:  1987-06-20

3.  Enhanced natural killer sensitivity with concomitant clonal selection for cells bearing homogeneously staining regions in the human melanoma cell line MeWo upon induction of differentiation with theophylline.

Authors:  T Haliotis; J A Werkmeister; I Louwman; S K Liao; J Matthews; R Riopelle; H F Pross; J J Holden; B N White; A Smith
Journal:  J Natl Cancer Inst       Date:  1984-05       Impact factor: 13.506

4.  Inhibition by caffeine of post-replication repair in Chinese hamster cells treated with cis platinum (II) Diamminedichloride: the extent of platinum binding to template DNA in relation to the size of low molecular weight nascent DNA.

Authors:  H W Van Den Berg; J J Roberts
Journal:  Chem Biol Interact       Date:  1976-03       Impact factor: 5.192

5.  Mechanism by which caffeine potentiates lethality of nitrogen mustard.

Authors:  C C Lau; A B Pardee
Journal:  Proc Natl Acad Sci U S A       Date:  1982-05       Impact factor: 11.205

Review 6.  Caffeine.

Authors:  J Timson
Journal:  Mutat Res       Date:  1977       Impact factor: 2.433

7.  In vivo and in vitro enhanced antitumor effects by pentoxifylline in human cancer cells treated with thiotepa.

Authors:  H J Fingert; A T Pu; Z Y Chen; P B Googe; M C Alley; A B Pardee
Journal:  Cancer Res       Date:  1988-08-01       Impact factor: 12.701

8.  Effect of inhibition of polyamine biosynthesis by DL-alpha-difluoromethylornithine on the growth and melanogenesis of B16 melanoma in vitro and in vivo.

Authors:  P S Sunkara; C C Chang; N J Prakash; P J Lachmann
Journal:  Cancer Res       Date:  1985-09       Impact factor: 12.701

Review 9.  DNA repair: relationship to drug and radiation resistance, metastasis and growth factors.

Authors:  A L Harris
Journal:  Int J Radiat Biol Relat Stud Phys Chem Med       Date:  1985-11

10.  Enhancement of melanotic expression in cultured mouse melanoma cells by retinoids.

Authors:  R Lotan; D Lotan
Journal:  J Cell Physiol       Date:  1981-02       Impact factor: 6.384

View more
  7 in total

Review 1.  Coffee consumption and the risk of cutaneous melanoma: a meta-analysis.

Authors:  Jia Wang; Xutong Li; Dongfeng Zhang
Journal:  Eur J Nutr       Date:  2015-12-22       Impact factor: 5.614

2.  Coffee, tea and melanoma risk: findings from the European Prospective Investigation into Cancer and Nutrition.

Authors:  Saverio Caini; Giovanna Masala; Calogero Saieva; Marina Kvaskoff; Isabelle Savoye; Carlotta Sacerdote; Oskar Hemmingsson; Bodil Hammer Bech; Kim Overvad; Anne Tjønneland; Kristina E N Petersen; Francesca Romana Mancini; Marie-Christine Boutron-Ruault; Iris Cervenka; Rudolf Kaaks; Tilman Kühn; Heiner Boeing; Anna Floegel; Antonia Trichopoulou; Elisavet Valanou; Maria Kritikou; Giovanna Tagliabue; Salvatore Panico; Rosario Tumino; H B As Bueno-de-Mesquita; Petra H Peeters; Marit B Veierød; Reza Ghiasvand; Marko Lukic; José Ramón Quirós; Maria-Dolores Chirlaque; Eva Ardanaz; Elena Salamanca Fernández; Nerea Larrañaga; Raul Zamora-Ros; Lena Maria Nilsson; Ingrid Ljuslinder; Karin Jirström; Emily Sonestedt; Timothy J Key; Nick Wareham; Kay-Tee Khaw; Marc Gunter; Inge Huybrechts; Neil Murphy; Konstantinos K Tsilidis; Elisabete Weiderpass; Domenico Palli
Journal:  Int J Cancer       Date:  2017-03-09       Impact factor: 7.396

3.  Caffeine Intake, Coffee Consumption, and Risk of Cutaneous Malignant Melanoma.

Authors:  Shaowei Wu; Jiali Han; Fengju Song; Eunyoung Cho; Xiang Gao; David J Hunter; Abrar A Qureshi
Journal:  Epidemiology       Date:  2015-11       Impact factor: 4.822

4.  In vitro enhancement of antitumor activity of a water-soluble duocarmycin derivative, KW-2189, by caffeine-mediated DNA-repair inhibition in human lung cancer cells.

Authors:  H Ogasawara; K Nishio; T Ishida; H Arioka; K Fukuoka; N Saijo
Journal:  Jpn J Cancer Res       Date:  1997-11

5.  1-Methyl-3-propyl-7-butylxanthine, a novel biochemical modulator, enhances therapeutic efficacy of adriamycin.

Authors:  Y Sadzuka; A Iwazaki; T Sugiyama; T Sawanishi; K Miyamoto
Journal:  Jpn J Cancer Res       Date:  1998-02

6.  Effects of methylxanthine derivatives on adriamycin concentration and antitumor activity.

Authors:  Y Sadzuka; A Iwazaki; A Miyagishima; Y Nozawa; S Hirota
Journal:  Jpn J Cancer Res       Date:  1995-06

7.  Caffeine modulates the antitumor activity and toxic side effects of adriamycin.

Authors:  Y Sadzuka; E Mochizuki; Y Takino
Journal:  Jpn J Cancer Res       Date:  1993-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.